非肝硬化门静脉系统血栓形成临床管理

doi:10.3969/j.issn.1672-5069.2024.01.003

Abstract

Lu Wenting, Zhang Feng. Clinical management of patients with non-cirrhotic portal veinthrombosis[J]. Journal of Practical Hepatology, 2024, 27(1): 7-10.

[1] Rajani R, Bjornsson E, Bergquist A, et al. The epidemiology and clinical features of portal vein thrombosis: a multicentre study. Aliment Pharmacol Ther, 2010,32(9):1154-1162.
[2] Hernández-Gea V, De Gottardi A, Leebeek FWG, et al. Current knowledge in patho-physiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral s-planchnic vein thrombosis. J Hepatol, 2019,71(1):175-199.
[3] Garcia-Pagán JC, Hernández-Guerra M, Bosch J. Extrahepatic portal vein thrombosis.Semin Liver Dis, 2008,28(03):282-292.
[4] Spaander VM, van Buuren HR, Janssen HL. The management of non-cirrhotic non-malignant portal vein thrombosis and concurrent portal hypertension in adults. Aliment Pharmacol Ther, 2007,26(s2):203-209.
[5] Iba T, Levy JH. Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis. J Thromb Haemost, 2018,16(2):231-241.
[6] Falanga A, Russo L, Milesi V, et al. Mechanisms and risk factors of thrombosis in cancer. Crit Rev Oncol Hematol, 2017,118:79-83.
[7] Stegner D, Dütting S, Nieswandt B. Mechanistic explanation for platelet contribution to cancer metastasis. Thromb Res, 2014,133:S149-S157.
[8] Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood, 2022,140(11):1200-1228.
[9] Elkrief L, Payancé A, Plessier A, et al. Management of splanchnic vein thrombosis. JHEP Rep, 2023,5(4):100667.
[10] Kiladjian JJ, Cassinat B. Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategies. Am J Hematol, 2023,98(5):794-800.
[11] Moliterno AR, Kaizer H. Applied genomics in MPN presentation. Hematology Am Soc Hematol Educ Program, 2020,2020(1):434-439.
[12] de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII – Renewing consensus in portal hypertension. J Hepatol, 2022,76(4):959-974.
[13] Bureau C, Laurent J, Robic MA, et al. Central obesity is associated with non-cirrhotic portal vein thrombosis. J Hepatol, 2016,64(2):427-432.
[14] Fontana L, Eagon JC, Trujillo ME, et al. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes, 2007,56(4):1010-1013.
[15] Mamad H, Benkirane S, El Aissaoui Y, et al. Prothrombotic disorders in non-cirrhotic, non-tumoral portal vein thrombosis. Thromb Res, 2021,203:152-154.
[16] De Broucker C, Plessier A, Ollivier-Hourmand I, et al. Multicenter study on recent p-ortal venous system thrombosis associated with cytomegalovirus disease. J Hepatol, 2022,76(1):115-122.
[17] Plessier A, Darwish-Murad S, Hernandez-Guerra M, et al. Acute portal vein thrombo-sis unrelated to cirrhosis: A prospective multicenter follow-up study. Hepatology, 2010,51(1):210-218.
[18] Llop E, Seijo S. Actuación ante la trombosis portal no cirrótica no tumoral. Gastroenterol Hepatol, 2016,39(6):403-410.
[19] Noronha Ferreira C, Seijo S, Plessier A, et al. Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis. Hepatology, 2016,63(5):1640-1650.
[20] Northup PG, Garcia-Pagan JC, Garcia-Tsao G, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 2021,73(1):366-413.
[21] Bettiol A, Alibaz-Oner F, Direskeneli H, et al. Vascular Behçet syndrome: from pathogenesis to treatment. Nat Rev Rheumatol, 2023,19(2):111-126.
[22] Sicre de Fontbrune F, Peffault de Latour R. Ten years of clinical experience with eculizumab in patients with paroxysmal mocturnal hemoglobinuria. Semin Hematol, 2018,55(3):124-129.
[23] Baiges A, Procopet B, Silva-Junior G, et al. Incidence and factors predictive of recurrent thrombosis in people with non-cirrhotic portal vein thrombosis. J Hepatol, 2023,78(1):114-122.
[24] Naymagon L, Tremblay D, Schiano T, et al. The role of anticoagulation in pylephle-bitis: a retrospective examination of characteristics and outcomes. J Thromb Thrombo-lysis, 2020,49(2):325-331.
[25] Burnett AE, Mahan CE, Vazquez SR, et al. Guidance for the practical management o-f the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis, 2016,41(1):206-232.
[26] Naymagon L, Tremblay D, Zubizarreta N, et al. The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis. Blood Adv, 2020,4(4):655-666.
[27] Mansour N, Öcal O, Gerwing M, et al. Interventional recanalization therapy in patients with non-cirrhotic, non-malignant portal vein thrombosis: comparison between transjugular versus transhepatic access. Abdom Radiol (NY), 2022,47(3):1177-1186.

Clinical management of patients with non-cirrhotic portal veinthrombosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Yu Shanshan, Zhang Yeting, Wang Yuanpeng, et al. Changes of serum MMP-1, MMP-2, TIMP-1 and HIF-1α levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2024, 27(3): 329-332.
[2]	Peng Yujing, Guo Hang, Chen Junguang. Liver fibrosis assessment by US elastography in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2024, 27(3): 345-348.
[3]	Cao Yanfen, Zou Haoxuan, Xie Yan. Diagnostic performance of atherogenic index of plasma in predicting patients with metabolic-associated fatty liver disease from physical examination population [J]. Journal of Practical Hepatology, 2024, 27(3): 361-365.
[4]	Gao Ping, Gao Xuesong, Zhang Yijin, et al. Clinical feature of patients with hemochromatosis: An analysis of 8 cases [J]. Journal of Practical Hepatology, 2024, 27(3): 386-389.
[5]	Bai Ping, Wang Han, Liu Rui, et al. Qualitative diagnosis of intrahepatic space-occupying lesions by multi-slice spiral CT and enhanced liver acquisition with volume acceleration [J]. Journal of Practical Hepatology, 2024, 27(3): 422-425.
[6]	Mei Wenjuan, Li Xin, Zhang Haoyue. Differentiation of hepatocellular carcinoma from metastatic liver cancer by time-intensity curve related parameters of contrast-enhanced ultrasonography [J]. Journal of Practical Hepatology, 2024, 27(3): 430-433.
[7]	Wang Qianwen, Hu Linlin, Xu Yunjun. Diagnostic performance of serum SPINK1 levels for hepatocellular carcinoma in patients with hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2024, 27(3): 442-445.
[8]	Shi Yu, Meng Linghui, Wang Luma. CT enhancement scan imaging feature of cholangiocellular carcinoma: An analysis of 18 cases [J]. Journal of Practical Hepatology, 2024, 27(3): 446-449.
[9]	Chen Ai’e, Peng Xiangqian, Chen Lina. Choice of open orlaparoscopic cholecystectomy under guidance of preoperative multi-slice spiral CT scan in patients with gallstones and cholecystitis [J]. Journal of Practical Hepatology, 2024, 27(3): 466-469.
[10]	Xu Jinghang, Yu Yanyan, Xu Xiaoyuan. Liver cirrhosis: Current state of the art [J]. Journal of Practical Hepatology, 2024, 27(2): 161-164.
[11]	Gao Guanghua, Hu Yan, Zheng Xue, et al.. Etiology and clinical feature in children with abnormal liver function tests: An analysis of 230 cases [J]. Journal of Practical Hepatology, 2024, 27(2): 173-176.
[12]	Guo Meng, Guo Qi, Zhang Feng. Evaluation of hepatic steatosis by controlled attenuation parameter of ultrasonic transient elastography in patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2024, 27(2): 189-192.
[13]	Li Min, Zhang Li, Zeng Ai, et al.. Liver fibrosis in patients with diabetes mellitus type 2 and non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2024, 27(2): 193-197.
[14]	Zheng Bo, Halida.Xiaerfuhazi, Tan Li. Changes of serum HIF-1α, HMGB1 and adiponectin levels in patients with non-alcoholic fatty liver diseases and their correlation to carotid atherosclerosis [J]. Journal of Practical Hepatology, 2024, 27(2): 198-201.
[15]	Tong Jing, Zhang Keli, Li Changping. Diagnostic performance of serum proneurotensin level and micro RNA load in patients with nonalcoholic steatohepatitis [J]. Journal of Practical Hepatology, 2024, 27(2): 202-205.